Addex Therapeutics Ltd (NASDAQ:ADXN – Free Report) – Equities researchers at HC Wainwright upped their FY2024 earnings per share (EPS) estimates for shares of Addex Therapeutics in a report released on Wednesday, October 2nd. HC Wainwright analyst R. Selvaraju now expects that the company will earn $0.49 per share for the year, up from their prior estimate of ($0.36). HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Addex Therapeutics’ current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Addex Therapeutics’ Q2 2025 earnings at $0.00 EPS, Q3 2025 earnings at $0.00 EPS, Q4 2025 earnings at $0.00 EPS and FY2025 earnings at ($0.28) EPS.
Addex Therapeutics Trading Up 0.4 %
Shares of ADXN stock opened at $9.44 on Friday. The stock has a market cap of $10.01 million, a P/E ratio of -0.55 and a beta of 1.79. Addex Therapeutics has a 1 year low of $5.00 and a 1 year high of $27.90. The stock has a 50 day simple moving average of $9.17 and a 200 day simple moving average of $10.57.
About Addex Therapeutics
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.
See Also
- Five stocks we like better than Addex Therapeutics
- 3 Grocery Stocks That Are Proving They Are Still Essential
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- What Are the FAANG Stocks and Are They Good Investments?
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for Addex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.